194 related articles for article (PubMed ID: 28148945)
41. Neoadjuvant trials could speed up drug approvals.
Peres J
J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
[No Abstract] [Full Text] [Related]
42. Room for improvement in breast cancer clinical trial design: taking advantage of the preoperative setting.
Kalinsky K; Hershman DL
J Comp Eff Res; 2013 Jul; 2(4):393-403. PubMed ID: 24236681
[TBL] [Abstract][Full Text] [Related]
43. The FDA and designing clinical trials for chronic cutaneous ulcers.
Maderal AD; Vivas AC; Eaglstein WH; Kirsner RS
Semin Cell Dev Biol; 2012 Dec; 23(9):993-9. PubMed ID: 23063664
[TBL] [Abstract][Full Text] [Related]
44. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
45. The FDA just says yes.
MacPherson P
Hosp Health Netw; 1996 May; 70(10):34-6, 38. PubMed ID: 8620201
[TBL] [Abstract][Full Text] [Related]
46. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
47. Looking for a miracle.
Marchant J
New Sci; 2000 Jun; 166(2244):16-7. PubMed ID: 11902203
[No Abstract] [Full Text] [Related]
48. The strange allure of state "right-to-try" laws.
Zettler PJ; Greely HT
JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
[No Abstract] [Full Text] [Related]
49. Clinical development success rates for investigational drugs.
Hay M; Thomas DW; Craighead JL; Economides C; Rosenthal J
Nat Biotechnol; 2014 Jan; 32(1):40-51. PubMed ID: 24406927
[No Abstract] [Full Text] [Related]
50. Investigational drug tracking: Phases I-III and NDA submissions--Part I.
Grant KL
Hosp Pharm; 1994 Sep; 29(9):830-6, 839-44, 847-52 passim. PubMed ID: 10137064
[TBL] [Abstract][Full Text] [Related]
51. Practical, legal, and ethical issues in expanded access to investigational drugs.
Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
[No Abstract] [Full Text] [Related]
52. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
Simon LS; Green A
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
[TBL] [Abstract][Full Text] [Related]
53. Early accelerated approval for highly targeted cancer drugs.
Chabner BA
N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
[No Abstract] [Full Text] [Related]
54. Tricky FDA debate: should a risky drug be approved again?
Mathews AW; Westphal SP
Wall St J (East Ed); 2006 Feb; ():B1, B4. PubMed ID: 16528879
[No Abstract] [Full Text] [Related]
55. EU law mandates drug testing in children.
Sinha G
J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
[No Abstract] [Full Text] [Related]
56. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
57. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
58. White House announces cancer-drug initiatives.
Am J Health Syst Pharm; 1996 May; 53(10):1110. PubMed ID: 8734669
[No Abstract] [Full Text] [Related]
59. Market watch: Upcoming market catalysts in Q3 2015.
Tan C
Nat Rev Drug Discov; 2015 Jul; 14(7):451. PubMed ID: 26092947
[No Abstract] [Full Text] [Related]
60. FDA treads delicate line between safety and speed.
Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
